Head-To-Head Analysis: Enliven Therapeutics (NASDAQ:ELVN) versus TransCode Therapeutics (NASDAQ:RNAZ)

Enliven Therapeutics (NASDAQ:ELVNGet Free Report) and TransCode Therapeutics (NASDAQ:RNAZGet Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Risk and Volatility

Enliven Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of -0.4, indicating that its share price is 140% less volatile than the S&P 500.

Insider & Institutional Ownership

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 40.4% of TransCode Therapeutics shares are held by institutional investors. 45.8% of Enliven Therapeutics shares are held by insiders. Comparatively, 1.5% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Enliven Therapeutics and TransCode Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enliven Therapeutics N/A -8.69% -8.37%
TransCode Therapeutics N/A -821.85% -267.58%

Valuation & Earnings

This table compares Enliven Therapeutics and TransCode Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enliven Therapeutics N/A N/A $1.49 million $3.20 5.14
TransCode Therapeutics N/A N/A -$17.57 million ($774.80) 0.00

TransCode Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Enliven Therapeutics and TransCode Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enliven Therapeutics 0 0 3 0 3.00
TransCode Therapeutics 0 0 1 0 3.00

Enliven Therapeutics presently has a consensus target price of $27.00, suggesting a potential upside of 64.18%. TransCode Therapeutics has a consensus target price of $480.00, suggesting a potential upside of 70,270.91%. Given TransCode Therapeutics’ higher probable upside, analysts plainly believe TransCode Therapeutics is more favorable than Enliven Therapeutics.

Summary

Enliven Therapeutics beats TransCode Therapeutics on 9 of the 10 factors compared between the two stocks.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado.

About TransCode Therapeutics

(Get Free Report)

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.